Denosumab in the treatment of glucocorticoid-induced osteoporosis: a systematic review and meta-analysis

OBJECTIVE: Glucocorticoid-induced osteoporosis (GIOP) is the most common form of secondary osteoporosis. In May 2018, denosumab was approved for the treatment of GIOP in men and women at high risk of fracture. We undertook a systematic review and meta-analysis to summarize the efficacy and safety of...

Descripción completa

Detalles Bibliográficos
Autores principales: Yanbeiy, Zeina A, Hansen, Karen E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6698580/
https://www.ncbi.nlm.nih.gov/pubmed/31616133
http://dx.doi.org/10.2147/DDDT.S148654

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6698580/
https://www.ncbi.nlm.nih.gov/pubmed/31616133
http://dx.doi.org/10.2147/DDDT.S148654

Ejemplares similares